Cancer Genetics Overview

  • Founded
  • 1999
Founded
  • Status
  • Public
  • Employees
  • 110
Employees
  • Stock Symbol
  • CGIX
Stock Symbol
  • Investments
  • 5
  • Share Price
  • $4.21
  • (As of Friday Closing)

Cancer Genetics General Information

Description

Cancer Genetics Inc through its vivoPharm subsidiary offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages, valued by the pharmaceutical industry, biotechnology companies, and academic research centers. The company is focused on precision and translational medicine to drive drug discovery and novel therapies. Its subsidiary, vivoPharm specializes in conducting studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug filings. VivoPharm operates in The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited and GLP compliant audited facilities.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 201 Route 17 North
  • 2nd Floor
  • Rutherford, NJ 07070
  • United States
+1 (201) 000-0000

Cancer Genetics Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Cancer Genetics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.21 $4.30 $1.92 - $10.39 $17.2M 4.09M 696K -$1.94

Cancer Genetics Financials Summary

In Thousands,
USD
TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 7,824 13,085 17,350 54,471
Revenue 6,329 7,305 4,932 29,121
EBITDA (3,057) (5,311) (3,106) (18,729)
Net Income (4,525) (6,708) (20,373) (20,880)
Total Assets 9,690 14,904 35,406 52,221
Total Debt 180 1,655 2,580 11,033
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cancer Genetics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cancer Genetics‘s full profile, request access.

Request a free trial

Cancer Genetics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Cancer Genetics‘s full profile, request access.

Request a free trial

Cancer Genetics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Cancer Genetics Inc through its vivoPharm subsidiary offers proprietary preclinical test systems supporting clinical dia
Pharmaceuticals
Rutherford, NJ
110 As of 2019
000.00
000000000 000.00

000000

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatu
0000 000000000
Princeton, NJ
000 As of 0000
00000
0000 0000-00-00
000000&0 00000

000 0000

sse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in
0000 000000000
Newark, DE
0000 As of 0000
000000000 -
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cancer Genetics Competitors (26)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aptuit Formerly PE-Backed Princeton, NJ 000 00000 000000&0 00000
000 00000000 Formerly PE-Backed Newark, DE 0000 000000000 -
00000000 Formerly VC-backed San Diego, CA 000 00000 000000&0 00000
00000000 Corporation Boston, MA 0 000.00 000000000 000.00
00000000000 Formerly VC-backed Portland, OR 000 000.00 000000&0 000.00
You’re viewing 5 of 26 competitors. Get the full list »

Cancer Genetics Executive Team (15)

Name Title Board Seat Contact Info
John Roberts Chief Executive Officer, President, Principal Financial Officer and Principal Accounting Officer
Glenn Miles Chief Financial Officer
You’re viewing 2 of 15 executive team members. Get the full list »

Cancer Genetics Board Members (8)

Name Representing Role Since
Edmund Cannon Self Board Member 000 0000
Franklyn Prendergast MD Self Board Member 000 0000
You’re viewing 2 of 8 board members. Get the full list »

Cancer Genetics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cancer Genetics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Cancer Genetics‘s full profile, request access.

Request a free trial

Cancer Genetics Acquisitions (5)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 24-Aug-2020 000000000000000000 Biotechnology 0000 0000000
000000000 15-Aug-2017 000000000000000000 00.00 Other Pharmaceuticals and Biotechnology 00000 000000
00000000 00000000 09-Oct-2015 000000000000000000 000.00 Diagnostic Equipment 000000 00000
0000000 16-Jul-2014 000000000000000000 00.000 Practice Management (Healthcare) 00000 000000
Cancer Genetics India 15-May-2014 Merger/Acquisition 00.00 Laboratory Services (Healthcare) 00000 000000
To view Cancer Genetics’s complete acquisitions history, request access »

Cancer Genetics Subsidiaries (2)

Company Name Industry Location Founded
vivoPharm Other Pharmaceuticals and Biotechnology Bundoora, Australia 2003
0000000 Practice Management (Healthcare) Morrisville, NC 0000
To view Cancer Genetics’s complete subsidiaries history, request access »

Cancer Genetics Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000 00000000 00 15-May-2014 000000000000000000 00.00 Completed
  • 000000 00000000
To view Cancer Genetics’s complete exits history, request access »